In a recent web seminar organized by Medcity News and sponsored by the business bank supplier* Mercury, the venture capitalists shared their perspectives on health technology, Medtech and the trends in the biofarma sector that have attracted their interest and financing. They also offered advice to new companies that seek alternative sources of financing beyond government subsidies.
Artificial intelligence and the impact of automation on tasks that require a lot of time, in part to identify objectives for drug development, were another important part of the discussion.
Gurdane Butani is a manager or MBX capital, an exclusive exclusive of the early stage company on medical and biotechnology companies that pursue the fundamental causes of why people get sick. Butani said that the company invests in three verticals: promoters upstream of human health results; Health technology companies that take advantage of AI to increase the quality of care; and biotechnology, diagnosis and therapeutic research tools. Butani’s training focused on epidemiology and toxicology.
Morgan Cheatham is a partner and head of Medical Care and Life Sciences with Breyer Capital, a risk firm founded by Jim Breyer, one of the first investors on Facebook. It focuses on investing in new stages companies at the intersection of medical care, life sciences and technology. Two or its key organization principles for investment are AI and precision medicine. Cheatham is also trained as a doctor in genetics.
Ben Kromnick built large learning and automatic learning platforms with Fortune 100 Health and Insurance companies before becoming a multiple clinical research founder, investor and operator. They worked with some of the clinical data sets, health systems and larger pharmaceutical companies. Using that experience, you are building the health and science business in Mercury.
In the Web Seminar, the panelists highlighted the investment and health starting strategies of their companies. Althegh AI was a dominant issue of the discussion, the panelists focused on the direct impact of their specialized applications in the field and their impact on capital valuations and corporate development strategies.
“If you are a company focused on autoimmune space and are developing a modulated agent, you should worry about immunogenicity as a key risk to your program,” said Cheatham. “Instead of focusing on AI as this great platform entity, Acrross, multiple indication areas, that company can develop highly specialized models that are specifically aimed at reducing immunogenicity for its success program.” Success. “Look.
Cheatham also pointed out the importance of living validation data that drives a large part of the external business development efforts that are embarked on Biofarma companies. These data in vivo drive the next financial milestones for new companies.